<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03561181</url>
  </required_header>
  <id_info>
    <org_study_id>201619306</org_study_id>
    <nct_id>NCT03561181</nct_id>
  </id_info>
  <brief_title>Safety Study of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months</brief_title>
  <official_title>A Single-center, Open, Phase I Clinical Trial to Evaluate Safety of S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine in Healthy Volunteers Aged Above 3 Months</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety of S.flexneriza-S.sonnei Bivalent Conjugate
      Vaccine in healthy volunteers aged above 3 Months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 18, 2017</start_date>
  <completion_date type="Actual">February 8, 2018</completion_date>
  <primary_completion_date type="Actual">January 28, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of adverse events during a 30 day follow-up period after each vaccination</measure>
    <time_frame>30 day after each vaccination</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Dysentery</condition>
  <condition>Dysentery, Bacillary</condition>
  <arm_group>
    <arm_group_label>High dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,10μg/dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low dose Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Received Vaccine: S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine,5μg/dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine</intervention_name>
    <description>Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.</description>
    <arm_group_label>High dose Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine</intervention_name>
    <description>Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg S.Flexneriza-S.Sonnei Bivalent Conjugate Vaccine.</description>
    <arm_group_label>low dose Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  3 months old and above healthy people.

          -  Subject or legal representative who consent and has signed written informed consent.

          -  Subject and parent/guardian who is able to comply with all study procedures.

          -  Subject who did't receive blood products within 30 days ,immune with any live vaccine
             within 14 days and inactivated vaccine within 7 days before vaccination.

          -  Axillary temperature ≤37.0 ℃.

        Exclusion Criteria:

          -  Febrile illness (temperature ≥ 38°C) in the 3 days.

          -  Subject who are allergic to tetanus toxoid.

          -  Allergic history after vaccination.

          -  Immunodeficiency diseases patients who administered with immunosuppressive agents.

          -  In pregnancy or lactation or pregnant women.

          -  Subject who are suffering from serious chronic diseases, infectious diseases, active
             infection, cardiovascular disease,liver or kidney disease.

          -  Subject who have symptoms such as diarrhea, abdominal pain, and pus and bloody stools
             in the past 3 days.

          -  History of allergy，eclampsia, epilepsy,brain trauma,encephalopathy and mental disease
             or family disease.

          -  Subject who diagnosis of thrombocytopenia or other history of coagulopathy may cause
             intramuscular contraindication.

          -  Children with abnormal labor（pregnancy week&lt;37w,&gt;42w）,birth weight (&lt;2500g,&gt;4000g),
             asphyxia rescue history,congenital malformations or developmental disorders(Only
             applicable to 3-5 months old group)

          -  Blood routine, blood chemistry and urinalysis laboratory collection abnormalities and
             the severity of grade 2 and above before immunization.

          -  Subject who plan to participate in or is in any other drug clinical trial.

          -  Any condition that, in the judgment of investigator, may affect trial assessment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Du lin, Master</last_name>
    <role>Study Chair</role>
    <affiliation>Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yizhou Center for Disease Control and Prevention</name>
      <address>
        <city>Yizhou</city>
        <state>Guangxi</state>
        <zip>546300</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>June 7, 2018</study_first_submitted>
  <study_first_submitted_qc>June 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2018</study_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysentery, Bacillary</mesh_term>
    <mesh_term>Dysentery</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

